Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CGEM
CULLINAN THERAPEUTICS, INC.
NASDAQ
$21.70
▼ DOWN 3.98% (-0.90)

KEY STATISTICS

Market Cap$1.33 B
52w High$23.19
52w Low$5.68
Dividend Yield—
Frequency—
P/E-7.00
Volume630.05K
Shares Out.61.46M

COMPANY

LEADERSHIP

Nadim Ahmed
CHIEF EXECUTIVE
Nadim Ahmed

COMPENSATION 2026

Salary$698,476
Stock Awards$1,697,400
Incentive Plan Pay$419,086
All Other Comp.$50,704
Total$5,100,006

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 8, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
109

PRICE TARGET

Target High$39.00
Target Low$27.00
Target Median$30.00
Target Consensus$32.20

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$2.00M
NOV
5
THU

PRICE

$21.70 ▼ DOWN 3.98% (−$0.90)
$21.60$21.90$22.20$22.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM21.70

About Cullinan Therapeutics, Inc.

https://cullinantherapeutics.com ↗

Cullinan Therapeutics, Inc., a Cambridge-based clinical-stage biopharmaceutical company founded in 2016, develops oncology and immuno-oncology therapies, including CLN-978, CLN-619, and others.

INDUSTRY

Biotechnology

A PRODUCT CULLINAN THERAPEUTICS, INC. IS KNOWN FOR

Zipalertinib
Zipalertinib

Zipalertinib is an investigational oral inhibitor targeting EGFR exon 20 insertion-mutant NSCLC, with Taiho Oncology submitting a rolling NDA to the FDA for accelerated approval, expected in early 2026.

COMPETITORS

COMPETITOR
AVBP COMPARE
BDTX COMPARE
IDYA COMPARE
JNJ COMPARE
SMMT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
142
LISTED HERE
22
RANKED BY POSITION SIZE
XBI
0.48% · 2.5M
VTI
0.00% · 2.0M
XSU.TO
0.04% · 1.6M
XS5G.L
0.07% · 323.0K
FESM
0.10% · 295.3K
SCHA
0.02% · 252.3K
DFMC
0.06% · 196.5K
TMSL
0.13% · 176.7K
AVSC
0.10% · 136.4K
PRFZ
0.07% · 93.6K
LABU
0.33% · 92.2K
CANC
0.67% · 65.8K
RSSL
0.04% · 28.9K
BBC
0.99% · 22.9K
WBIO.L
1.14% · 16.7K
RTWO.L
0.06% · 5.9K
TILT
0.00% · 3.8K
URTY
0.02% · 2.5K
PWS
0.10% · 1.1K
TMFX
0.05% · 890
USFMDN.MX
0.00% · 185
RESM
0.03% · 90

INSTITUTIONAL OWNERSHIP

SHARES OWNED
91.10%
HOLDERS
237
TOP 12 OF 237 · RANKED BY POSITION SIZE
Bioimpact Capital LLC
9.7M sh · $177.21M
Lynx1 Capital Management LP
9.0M sh · $127.37M
Bvf Inc/Il
5.8M sh · $81.72M
Blackrock, Inc.
5.2M sh · $95.29M
Price T Rowe Associates Inc /Md/
3.8M sh · $69.67M
State Street Corp
3.7M sh · $66.81M
Blackrock Inc.
3.6M sh · $61.92M
Chi Advisors LLC
3.4M sh · $30.9M
Vanguard Group Inc
3.3M sh · $34.14M
Kynam Capital Management, LP
3.1M sh · $32.23M
Deerfield Management Company, L.P. (Series C)
2.9M sh · $17.36M
Blue Owl Capital Holdings LP
2.5M sh · $14.89M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Michaelson Jennifer
Purchase · 30.0K shares
2026-08-13
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Michaelson Jennifer
Sale · 30.0K shares
2026-08-13
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Michaelson Jennifer
Sale · 4.0K shares
2026-07-06
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Michaelson Jennifer
Purchase · 4.0K shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Wedbush OUTPERFORM BTIG BUY

SECTORS PEERS

PEERPRICE
OMER$18.61COMPARE
CBLL$23.73COMPARE
VREX$18.50COMPARE
SY$2.40COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
LAB$0.64COMPARE
ADCT$1.14COMPARE